BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Trerief zonisamide: Phase II started

Dainippon disclosed in its fiscal 2Q13 earnings for the 6 months ended Sept. 30 that it began a double-blind, placebo-controlled, Japanese Phase II trial to evaluate oral Trerief in about 150 patients. Eisai markets zonisamide for partial...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >